Logo image of SBTX

SILVERBACK THERAPEUTICS INC (SBTX) Stock Fundamental Analysis

NASDAQ:SBTX - Nasdaq - US82835W1080 - Common Stock - Currency: USD

5.87  +0.06 (+1.03%)

Fundamental Rating

2

Overall SBTX gets a fundamental rating of 2 out of 10. We evaluated SBTX against 571 industry peers in the Biotechnology industry. While SBTX seems to be doing ok healthwise, there are quite some concerns on its profitability. SBTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SBTX had negative earnings in the past year.
SBTX had a negative operating cash flow in the past year.
SBTX Yearly Net Income VS EBIT VS OCF VS FCFSBTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -31.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SBTX Yearly ROA, ROE, ROICSBTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SBTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SBTX Yearly Profit, Operating, Gross MarginsSBTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021

More info and screens

6

2. Health

2.1 Basic Checks

SBTX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for SBTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SBTX Yearly Shares OutstandingSBTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 10M 20M 30M
SBTX Yearly Total Debt VS Total AssetsSBTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

SBTX has an Altman-Z score of 30.54. This indicates that SBTX is financially healthy and has little risk of bankruptcy at the moment.
SBTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 30.54
ROIC/WACCN/A
WACCN/A
SBTX Yearly LT Debt VS Equity VS FCFSBTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M 200M 300M

2.3 Liquidity

SBTX has a Current Ratio of 67.87. This indicates that SBTX is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 67.87 indicates that SBTX has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 67.87
Quick Ratio 67.87
SBTX Yearly Current Assets VS Current LiabilitesSBTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for SBTX have decreased by -6.10% in the last year.
EPS 1Y (TTM)-6.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.17% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.29%
EPS Next 2Y8.78%
EPS Next 3Y4.57%
EPS Next 5Y5.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SBTX Yearly Revenue VS EstimatesSBTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026
SBTX Yearly EPS VS EstimatesSBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SBTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SBTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SBTX Price Earnings VS Forward Price EarningsSBTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.42
SBTX Per share dataSBTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.78%
EPS Next 3Y4.57%

More info and screens

0

5. Dividend

5.1 Amount

SBTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SILVERBACK THERAPEUTICS INC

NASDAQ:SBTX (11/8/2022, 4:30:02 PM)

5.87

+0.06 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2022-08-11/amc
Earnings (Next)11-22 2022-11-22/amc
Inst Owners179.25%
Inst Owner Change-85.23%
Ins Owners3.19%
Ins Owner Change0%
Market Cap210.63M
Analysts43.33
Price Target5.1 (-13.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.56%
Min EPS beat(2)-11.56%
Max EPS beat(2)-11.56%
EPS beat(4)1
Avg EPS beat(4)-11.06%
Min EPS beat(4)-28.04%
Max EPS beat(4)6.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA 1.42
EPS(TTM)-2.56
EYN/A
EPS(NY)-2.09
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.03
OCFYN/A
SpS0
BVpS7.44
TBVpS7.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 67.87
Quick Ratio 67.87
Altman-Z 30.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.16%
EPS Next Y26.29%
EPS Next 2Y8.78%
EPS Next 3Y4.57%
EPS Next 5Y5.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.83%
EBIT Next 3Y6.2%
EBIT Next 5Y4.27%
FCF growth 1Y-177.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-179.49%
OCF growth 3YN/A
OCF growth 5YN/A